A Cell Cycle Progression-Derived Gene Signature to Predict Prognosis and Therapeutic Response in Hepatocellular Carcinoma

Figure 3

Construction of a CCP-derived prognostic gene signature for HCC in TCGA-LIHC cohort. (a) The change in trajectory of candidate variables. The -axis represented the log (lambda) of variables, and the -axis represented the coefficient of variables. (b) Partial likelihood deviance corresponding to each lambda. (c) The interactions between six candidate genes in the LASSO model. (d) Distribution of CCP-derived RS in each HCC patient. The high- and low-risk groups were separated in line with the median of RS (dotted line). (e) Distribution of survival status in high- and low-risk groups. (f) Heat map visualizing the mRNA expression of six candidate variables in high- and low-risk groups. Yellow, upregulation and blue, downregulation. (g) Prognostic analyses of HCC patients with high and low RS in TCGA-LIHC cohort. (h–o) Comparison of survival outcomes of HCC patients with high and low RS in each subgroup of and , female and male, G1-2 and G3-4, and stages I-II and stages III-IV.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)

(n)

(o)